Multidisciplinary Management of Hepatocellular Carcinoma

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 4, 2012, Pages 354-362

  Guy, Jennifer ^a,b   Kelley, Robin K ^a,b   Roberts, John ^a,b   Kerlan, Robert ^a,b   Yao, Francis ^a,b   Terrault, Norah ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatocellular carcinoma; Resection; Transplantation

Indexed keywords

ADI PEG 20; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BILIRUBIN; BRIVANIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; LINIFANIB; PLACEBO; RAMUCIRUMAB; SORAFENIB; SUNITINIB; THALIDOMIDE; THYMOPENTIN; UNCLASSIFIED DRUG; YTTRIUM 90;

ADVANCED CANCER; ARTIFICIAL EMBOLISM; BILIRUBIN BLOOD LEVEL; BLEEDING; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; OVERALL SURVIVAL; REVIEW; SIDE EFFECT; SKIN MANIFESTATION;

CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84858709202     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.11.008     Document Type: Review

References (81)

1. El-Serag H.B., Marrero J.A., Rudolph L., et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008, 134:1752-1763.
2. Kim W.R., Gores G.J., Benson J.T., et al. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology 2005, 129:486-493.
3. Lang K., Danchenko N., Gondek K., et al. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009, 50:89-99.
4. Cabibbo G., Enea M., Attanasio M., et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010, 51:1274-1283.
5. Pelletier S.J., Fu S., Thyagarajan V., et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transplant 2009, 15:859-868.
6. Wong R.J., Corley D.A. Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States. Dig Dis Sci 2009, 54:2031-2039.
7. El-Serag H.B., Siegel A.B., Davila J.A., et al. Treatment and outcomes of treating hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006, 44:158-166.
8. Llovet J.M., Schwartz M., Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005, 25:181-200.
9. Pons F., Varela M., Llovet J.M. Staging systems in hepatocellular carcinoma. HPB (Oxford) 2005, 7:35-41.
10. Llovet J.M., Brú C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
11. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022. American Association for the Study of Liver Diseases.
12. Cabibbo G., Latteri F., Antonucci M., et al. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol 2009, 6:159-169.
13. Vauthey J.N., Lauwers G.Y., Esnaola N.F., et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002, 20:1527-1536.
14. Takayama T., Makuuchi M., Hirohashi S., et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998, 28:1241-1246.
15. Ikai I., Arii S., Kojiro M., et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004, 101:796-802.
16. Zhou X.D., Tang Z.Y., Yang B.H., et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001, 91:1479-1486.
17. Nathan H., Schulick R.D., Choti M.A., et al. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 2009, 249:799-805.
18. Livraghi T., Meloni F., Di Stasi M., et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?. Hepatology 2008, 47:82-89.
19. Rhim H., Lim H.K., Choi D. Current status of radiofrequency ablation of hepatocellular carcinoma. World J Gastrointest Surg 2010, 2:128-136.
20. Sala M., Llovet J.M., Vilana R., et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004, 40:1352-1360.
21. Llovet J.M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 30:1434-1440.
22. Cho Y.K., Kim J.K., Kim W.T., et al. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 2010, 51:1284-1290.
23. Cho Y.K., Kim J.K., Kim M.Y., et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009, 49:453-459.
24. Chok K.S., Ng K.K., Poon R.T., et al. Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization. Arch Surg 2006, 141:1231-1236.
25. Shibata T., Isoda H., Hirokawa Y., et al. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?. Radiology 2009, 252:905-913.
26. Marelli L., Stigliano R., Triantos C., et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006, 32:594-606.
27. Naugler W.E., Sonnenberg A. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transplant 2010, 16:1186-1194.
28. Rossi S., Ravetta V., Rosa L., et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology 2011, 53:136-147.
29. Freeman R.B., Edwards E.B., Harper A.M. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 2006, 6:1416-1421.
30. Roberts J.P., Venook A., Kerlan R., et al. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transplant 2010, 16:925-929.
31. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531.
32. Singal A.K., Freeman D.H., Anand B.S. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010, 32:851-858.
33. Mazzaferro V., Romito R., Schiavo M., et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006, 44:1543-1554.
34. Ishizawa T., Hasegawa K., Aoki T., et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008, 134:1908-1916.
35. Poon R.T. Liver transplantation for solitary hepatocellular carcinoma less than 3 cm in diameter in Child A cirrhosis. Dig Dis 2007, 25:334-340.
36. Koike Y., Shiratori Y., Sato S., et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 2000, 32:1216-1223.
37. Pawlik T.M., Delman K.A., Vauthey J.N., et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transplant 2005, 11:1086-1092.
38. Roayaie S., Blume I.N., Thung S.N., et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009, 137:850-855.
39. Hoshida Y., Villanueva A., Kobayashi M., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008, 359:1995-2004.
40. Villanueva A., Hoshida Y., Battiston C., et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011, 140:1501-1512.
41. Chen M.S., Li J.Q., Zheng Y., et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006, 243:321-328.
42. Lencioni R., Cioni D., Crocetti L., et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005, 234:961-967.
43. N'Kontchou G., Mahamoudi A., Aout M., et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009, 50:1475-1483.
44. Santambrogio R., Opocher E., Zuin M., et al. Surgical resection versus laparoscopic radiofrequency ablation in patients with hepatocellular carcinoma and Child-Pugh class A liver cirrhosis. Ann Surg Oncol 2009, 16:3289-3298.
45. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
46. Ioannou G.N., Perkins J.D., Carithers R.L. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008, 134:1342-1351.
47. Pomfret E.A., Washburn K., Wald C., et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transplant 2009, 16:262-278.
48. Freeman R.B., Steffick D.E., Guidinger M.K., et al. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008, 8:958-976.
49. Lesurtel M., Müllhaupt B., Pestalozzi B.C., et al. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006, 6:2644-2650.
50. Mazzaferro V., Battiston C., Perrone S., et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004, 240:900-909.
51. Maddala Y.K., Stadheim L., Andrews J.C., et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transplant 2004, 10:449-455.
52. Scatton O., Zalinski S., Terris B., et al. Hepatocellular carcinoma developed on compensated cirrhosis: resection as a selection tool for liver transplantation. Liver Transplant 2008, 14:779-788.
53. Belghiti J., Cortes A., Abdalla E.K., et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003, 238:885-892. discussion, 892-893.
54. Adam R., Azoulay D., Castaing D., et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?. Ann Surg 2003, 238:508-518. discussion, 518-519.
55. Pomfret E.A., Washburn K., Wald C., et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transplant 2010, 16:262-278.
56. Poon R.T., Fan S.T., Lo C.M., et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002, 235:373-382.
57. Lo C.M., Fan S.T., Liu C.L., et al. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 2007, 94:78-86.
58. Fisher R.A., Kulik L.M., Freise C.E., et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007, 7:1601-1608.
59. Bhangui P., Vibert E., Majno P., et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology 2011, 53:1570-1579.
60. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394-1403.
61. Duffy J.P., Vardanian A., Benjamin E., et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007, 246:502-509. discussion, 509-511.
62. Mazzaferro V., Llovet J.M., Miceli R., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10:35-43.
63. Guiteau J.J., Cotton R.T., Washburn W.K., et al. An early regional experience with expansion of Milan criteria for liver transplant recipients. Am J Transplant 2010, 10:2092-2098.
64. D'Amico F., Schwartz M., Vitale A., et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transplant 2009, 15:1278-1287.
65. Millonig G., Graziadei I.W., Freund M.C., et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transplant 2007, 13:272-279.
66. Otto G., Herber S., Heise M., et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transplant 2006, 12:1260-1267.
67. Yao F.Y., Kerlan R.K., Hirose R., et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008, 48:819-827.
68. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
69. Varela M., Real M.I., Burrel M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007, 46:474-481.
70. Lammer J., Malagari K., Vogl T., et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol 2010, 33:41-52.
71. Salem R., Lewandowski R.J., Kulik L., et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011, 140:497-507.e2.
72. Hilgard P., Hamami M., Fouly A.E., et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010, 52:1741-1749.
73. Kulik L.M., Carr B.I., Mulcahy M.F., et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008, 47:71-81.
74. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
75. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
76. Miller A.A., Murry D.J., Owzar K., et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009, 27:1800-1805.
77. Lencioni R., Marrero J., Venook A., et al. Design and rationale for the non-interventional global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) study. Int J Clin Pract 2010, 64:1034-1041.
78. Iavarone M., Cabbibo G., Piscaglia F., et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011, 54:2055-2063.
79. Carr B.I., Carroll S., Muszbek N., et al. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 2010, 25:1739-1746.
80. Villanueva A., Llovet J.M. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011, 140:1410-1426.
81. Bruix J., Llovet J.M. Major achievements in hepatocellular carcinoma. Lancet 2009, 373:614-616.